Business Update Positive

2026-08-25 20:41

- Crisil Ratings reaffirmed the Company's credit ratings. - Long Term Rating: CRISIL A+/Positive, with outlook revised to 'Positive'. - Short Term Rating: CRISIL A1, reaffirmed.

Business Update Negative

2026-08-14 18:56

CRITICAL RED FLAG DETECTED

- US FDA inspected Neuland Laboratories' Unit 3 facility from August 10-14, 2026. - A Form 483 was issued with one observation related to procedural improvements in water and environmental monitoring. - The company will submit its response to the FDA.

Business Update Positive

2026-08-10 18:59

- Neuland Laboratories reported strong Q1FY27 performance, with Total Income at INR 650.1 crores compared to INR 300.6 crores in Q1FY26 (▲116.3% YoY). - Profit After Tax (PAT) significantly increased to INR 147.4 crores from INR 13.7 crores in Q1FY26 (▲976.0% YoY), with EBITDA margin at 35.5%. - Management expects revenue growth of approximately 20% for FY27 and FY28, with FY27 anticipated as a year of overall growth. - Long-term EBITDA margin expectation is "25% plus," with current expectations for higher EBITDA. - A new peptide manufacturing plant is scheduled for commissioning next month, already having multiple projects lined up. - A strategic collaboration with Gland Pharma has been established to develop a differentiated platform in sterile APIs, seen as a long-term partnership. - The company is making significant investments in R&D, peptide, and sterile API capabilities, with future capital expenditure expected to be higher and focused on newer, more complex modalities. - Development revenue is projected to increase in FY27, with more molecules expected to contribute to commercial revenue from FY28 onwards.

Business Update Neutral

2026-08-07 13:45

- Analyst/Institutional Investor Meeting Scheduled - Meeting Date: August 12, 2026 - Event: Emkay Confluence 2026 - Location: Mumbai - Nature of Meeting: Group meet / One-on-One meet

Business Update Neutral

2026-08-05 22:23

- Audio recording of the Earnings call conducted on August 5, 2026, for the quarter ended June 30, 2026, is now available. - Weblink for access: https://www.neulandlabs.com/en/investors/investor-meetings/investor-call-recordings.

Financials Positive

2026-08-05 16:40

- Consolidated Revenue ₹64,157.71 lakhs vs ₹29,275.27 lakhs (▲119.15% YoY) - EBITDA ₹22,289.04 lakhs vs ₹3,448.89 lakhs (▲546.12% YoY) - PAT ₹14,767.31 lakhs vs ₹1,390.00 lakhs (▲962.39% YoY) - EBITDA Margin 34.74% vs 11.78% (▲2296bps) - Board approved a Corporate Guarantee of ₹40 crores in favour of Gland Pharma Limited for a Loan Licence Agreement to establish dedicated manufacturing capacity. - Approved enhancement of manufacturing capacity at Unit 1 by 18 KL for ₹39.8 crores (incl GST), funded by internal accruals, to meet growing customer demand. - Announced a strategic CDMO partnership with Gland Pharma for sterile API manufacturing, involving a new cGMP state-of-the-art sterile suite to add approximately 1400 kg of annual capacity.

Financials Positive

2026-08-05 16:33

- Consolidated Revenue ₹641.58Cr vs ₹292.75Cr (▲119.14% YoY) - EBITDA ₹222.89Cr vs ₹34.49Cr (▲546.28% YoY) - PAT ₹147.67Cr vs ₹13.90Cr (▲962.37% YoY) - EBITDA Margin 34.74% vs 11.78% (▲2296bps) - Board approved a Corporate Guarantee of ₹40 crores for a Loan Licence Agreement with Gland Pharma Limited to establish dedicated manufacturing capacity. - Approved enhancement of manufacturing capacity at Unit 1 by 18 KL with an investment of ₹39.8 crores, to be funded through internal accruals. - Announced a long-term strategic CDMO partnership with Gland Pharma for sterile API manufacturing, including a new dedicated sterile suite with ~1400 kg annual capacity.

Financials Positive

2026-08-05 16:18

- Consolidated Total Income ₹650.1 Cr vs ₹300.6 Cr (▲116.3% YoY) - EBITDA ₹231.1 Cr vs ₹42.1 Cr (▲448.2% YoY) - PAT ₹147.4 Cr vs ₹13.7 Cr (▲975.0% YoY) - EBITDA Margin 35.5% vs 14.0% (▲2150bps)

Financials Positive

2026-08-05 16:05

- Consolidated Revenue ₹641.58Cr vs ₹292.75Cr (▲119.16% YoY) - EBITDA ₹222.89Cr vs ₹34.49Cr (▲546.25% YoY) - PAT ₹147.67Cr vs ₹13.90Cr (▲962.37% YoY) - EBITDA Margin 34.74% vs 11.78% (▲2296bps) - Board approved a Corporate Guarantee of ₹40 crores for a Loan Licence Agreement with Gland Pharma Limited to establish dedicated manufacturing capacity. - Approved an 18 KL manufacturing capacity addition at Unit 1, costing ₹39.8 crores, to be completed in 6-7 months via internal accruals. - Announced a strategic CDMO partnership with Gland Pharma for sterile API manufacturing, including Gland Pharma establishing a dedicated sterile manufacturing suite with approx. 1400 kg annual capacity for Neuland.

Governance Positive

2026-08-04 17:39

- The 42nd Annual General Meeting (AGM) of Neuland Laboratories Limited was held on August 4, 2026, where all resolutions were passed with requisite majority. - Shareholders approved the Audited Financial Statements for the financial year ended March 31, 2026. - A final dividend of Rs. 34.00/- (340%) per equity share for FY2025-26 was declared. - Resolutions for the re-appointment of Dr. Davuluri Rama Mohan Rao and appointment of Dr. Mauricio Futran as Non-Executive Non-Independent Director were also passed.

Business Update Positive

2026-07-31 22:12

- Neuland Laboratories commenced commercial production of additional capacities at its Unit 1 (Bonthapally Village) and Unit 3 (Gaddapotharam Village) in Sangareddy District, Telangana, as part of its expansion plans.

Business Update Neutral

2026-07-28 11:53

- Concall Schedule for Q1 FY27 Earnings Conference Call - Concall Date: August 05, 2026 - Concall Time: 17:30 Hrs (IST)

Business Update Neutral

2026-07-13 17:39

- India Ratings and Research affirmed the credit rating for Neuland Laboratories Limited's bank loan facilities. - The rating remains IND A+/ Positive/ IND A1.

Routine Neutral

2026-07-09 20:26

New Filing detected. See link for details.

Routine Neutral

2026-07-09 19:42

New Filing detected. See link for details.

Governance Positive

2026-07-09 19:10

- Notice for the 42nd Annual General Meeting on August 4, 2026, at 10:00 a.m. via VC/OAVM. - Agenda includes adopting FY2025-26 financial statements and declaring a final dividend of ₹34/- per equity share. - Also covers re-appointment of Dr. D.R.M. Rao and appointment of Dr. M. Futran as Non-Executive Non-Independent Director.

Governance Neutral

2026-06-25 17:43

- Trading window for equity shares will close from July 1, 2026, until 48 hours after Q1 FY27 financial results declaration (quarter ended June 30, 2026). - The date of the Board Meeting for Q1 FY27 results will be intimated in due course.

Business Update Neutral

2026-06-05 09:59

- Analyst/Institutional Investor Meeting Schedule - Meeting Date: June 11, 2026 - Event: Goldman Sachs Non-deal roadshow (NDR) - Location: Hyderabad - Nature of meeting: Group meet / One-on-One meet

Business Update Neutral

2026-06-03 15:01

- Concall Schedule - Concall Date: June 8 & 9, 2026 - Event: Nuvama India Conference 2026 (UK Edition) - Location: London, United Kingdom - Meeting Type: Group meet / One-on-One meet

Business Update Neutral

2026-05-31 19:15

Neuland Laboratories Limited's management will participate in a group/one-on-one meeting with analysts and institutional investors from BOFA Healthcare Tour on June 5, 2026, in Hyderabad. This filing serves as an intimation of the scheduled investor interaction.

Business Update Neutral

2026-05-22 16:36

Neuland Laboratories Limited announced that its management will participate in the 360 ONE Capital(B&K) 16th Annual Investor Conference - TRINITY INDIA 2026 in Mumbai on May 28, 2026. The meeting will include group and one-on-one sessions with analysts and institutional investors.

Business Update Positive

2026-05-16 16:14

Management guided for an aspirational 18-20% CAGR over a 5-year period, expressing confidence in long-term growth driven by existing and new commercial molecules, particularly the significant $5-6 billion market opportunity in peptides. The company incurred a Capex outflow of INR397.1 crores in FY26 for large-scale peptide commercial facilities and a new R&D center, with the peptide facility on track to be operational by July. While FY26 free cash flow was negative due to investments and increased working capital (expected to normalize in FY27), the balance sheet remains strong with negative net debt. Management acknowledges quarterly business lumpiness and supply chain volatility but focuses on execution discipline and strategic capital allocation for future expansion.

Business Update Neutral

2026-05-12 19:49

Neuland Laboratories Limited announced the availability of the audio recording of its earnings call, which was conducted on May 12, 2026. The call discussed the financial results for the quarter and year ended March 31, 2026. A weblink to access the recording has been provided.

Financials Positive

2026-05-12 19:26

For the year ended March 31, 2026, Consolidated Revenue from operations increased to ₹2023Cr vs ₹1477Cr (▲37% YoY), EBITDA to ₹575Cr vs ₹410Cr (▲40% YoY), and PAT to ₹364Cr vs ₹260Cr (▲40% YoY). EBITDA Margin expanded to 28.4% vs 27.7% (▲65bps). The company recommended a final dividend of Rs. 34/- per equity share for FY2025-26 and approved a capacity enhancement of 120.5 KL at Unit 1 with a ₹143.4 crore investment, to be completed in 12-18 months.

Financials Positive

2026-05-12 19:17

Consolidated Revenue ₹788.7Cr vs ₹335.8Cr (▲134.9% YoY), EBITDA ₹319.4Cr vs ₹58.2Cr (▲448.6% YoY), PAT ₹212.5Cr vs ₹27.7Cr (▲666.3% YoY). EBITDA Margin 40.5% vs 17.3% (▲2316bps).

Financials Positive

2026-05-12 18:51

Neuland Laboratories reported strong Q4FY26 results: Total Income ₹788.7 Cr vs ₹335.8 Cr (▲134.9% YoY), EBITDA ₹319.4 Cr vs ₹58.2 Cr (▲448.6% YoY), PAT ₹212.5 Cr vs ₹27.7 Cr (▲666.3% YoY). EBITDA Margin expanded significantly from 17.3% to 40.5% (▲2316bps). Management expressed satisfaction with ending FY26 on a strong note, in line with expectations, and noted good business visibility.

Financials Positive

2026-05-12 18:50

Neuland Laboratories Limited's Board approved the Audited Annual Financial Results for FY 2025-26 and recommended a final dividend of Rs. 34/- (340%) per equity share. The company plans to enhance capacity at Unit 1 by 120.5 KL, investing ₹143.4 crores over 12-18 months to meet growing demand. Dr. Mauricio Futran was appointed as an Additional Director.

Financials Positive

2026-05-12 18:50

The Board approved the Audited Financial Results for the year ended March 31, 2026, and recommended a final dividend of Rs. 34/- (340%) per equity share for FY 2025-26. Dr. Mauricio Futran was appointed as an Additional Director. The 42nd Annual General Meeting (AGM) will be held on August 4, 2026, with July 24, 2026, as the record date for the dividend. The company also approved a capacity enhancement of 120.5 KL at Unit 1, requiring an investment of ₹143.4 crores, to be completed within 12-18 months.

Financials Positive

2026-05-12 18:49

Neuland Laboratories Limited's Board approved Audited Annual Financial Results for FY2025-26 and recommended a final dividend of Rs. 34/- per equity share. To meet growing demand, the company announced a capacity enhancement of 120.5 KL at Unit 1 with an investment of Rs. 143.4 crores, funded by internal accruals and borrowings. Dr. Mauricio Futran was also appointed as an Additional Director.

Business Update Positive

2026-05-12 18:48

Neuland Laboratories' Board approved annual financial results for FY2025-26 and recommended a final dividend of Rs. 34/- (340%) per equity share. Dr. Mauricio Futran was appointed as an Additional Director (Non-Executive Non-Independent) effective May 12, 2026. The company announced a capacity expansion at Unit 1 by 120.5 KL, investing ₹143.4 crores, to be completed in 12-18 months to meet growing demand. The 42nd AGM is scheduled for August 4, 2026, with July 24, 2026, as the record date.

Financials Positive

2026-05-12 16:49

Consolidated Total Income ₹788.7Cr vs ₹335.8Cr (▲134.9% YoY), EBITDA ₹319.4Cr vs ₹58.2Cr (▲448.6% YoY), PAT ₹212.5Cr vs ₹27.7Cr (▲666.3% YoY). EBITDA Margin 40.5% vs 17.3% (▲2320bps). Management highlighted strong performance in line with expectations, good business visibility, and investments in Peptide Manufacturing and a new R&D Centre for future growth.

Financials Positive

2026-05-12 16:27

Consolidated Revenue for the quarter ended March 31, 2026, was ₹788.71Cr vs ₹335.82Cr (▲134.89% YoY), EBITDA ₹307.33Cr vs ₹51.07Cr (▲501.74% YoY), PAT ₹212.67Cr vs ₹27.81Cr (▲664.12% YoY). EBITDA Margin expanded to 38.97% vs 15.21% (▲2376bps). The Board also recommended a final dividend of ₹34 per share for FY26 and approved a capacity expansion project of 120.5 KL at Unit 1 with an investment of ₹143.4 crores.

Financials Positive

2026-05-12 16:25

Consolidated annual results for the year ended March 31, 2026: Revenue from operations ₹2,022.99 Cr vs ₹1,476.84 Cr (▲37.0% YoY), EBITDA ₹574.50 Cr vs ₹399.66 Cr (▲43.7% YoY), PAT ₹364.00 Cr vs ₹260.11 Cr (▲39.9% YoY). EBITDA Margin 28.39% vs 27.06% (▲133bps). The board recommended a final dividend of ₹34/- per equity share for FY26 and approved a 120.5 KL capacity expansion at Unit 1 with a ₹143.4 Cr investment to meet growing demand.

NEULANDLAB

Neuland Laboratories Limited

Price Chart

Filing History

Unlock Full History